Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Efamarine is a nutritional supplement product marketed by Efamol, designed to support joint health, mobility, and cardiovascular function. It consists of a specific combination of **evening primrose oil** (providing the omega-6 fatty acid gamma-linolenic acid, GLA) and **marine fish oil** (providing the omega-3 fatty acids eicosapentaenoic acid, EPA, and docosahexaenoic acid, DHA), supplemented with **vitamin E**. The formulation relies on the synergistic effects of these essential fatty acids to modulate inflammatory pathways, specifically by serving as precursors for anti-inflammatory eicosanoids and competing with arachidonic acid for metabolic enzymes. It is sold as a dietary supplement in softgel capsule form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Efamarine.